Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

Figure 6

Enavatuzumab stimulates an increase in cytokine levels in some tumor cell cultures. (a) A375, SN12C, HCT116, and DLD-1 cells were treated with enavatuzumab or a control antibody for 24 hr, after which the levels GM-CSF, IL-6, IL-8, and MCP-1 were measured in the supernatants by Luminex multiplex assays (, ). (b) A375 cells were plated into the bottom of Transwell plates and treated with enavatuzumab or a control antibody for 24 hr, after which antibodies blocking MCP-1 (left) or IL-8 (right) were added for 0.5 hr. PBMCs were then added to the top of the Transwell; 4 hr later, the number of immune cells that had migrated toward the tumor cells was quantified by flow cytometry (, ).

(a)

(b)